Rising Prevalence of Diabetes Fuels Demand for Diabetic Nephropathy Therapeutics

Published By : 30 May 2016 | Published By : QYRESEARCH

The global market for diabetic nephropathy has been reporting an exponential rise in its valuation. The increasing prevalence of diabetes and other kidney-related disorders globally, propelled by the growing geriatric and obese population, is fueling the demand for diabetic nephropathy therapeutics across the world.

ACE Inhibitors Emerge as Leading DMT in Global Diabetic Nephropathy Market
Disease modifying therapy (DMT) is the only mode of treatment for diabetic nephropathy in the global market. ACE inhibitors, ARBs, renin inhibitors, diuretics, calcium channel blockers, monocyte chemoattractant protein inhibitors, connective tissue growth factor inhibitors, antioxidant inflammation modulators, endothelin-A receptor antagonist, and G protein-coupled receptors are the major types DMT available across the world. Among these, the ACE inhibitors segment enjoys the highest demand.

Asia to Register Fastest Growth in Global Diabetic Nephropathy Market
The global diabetic nephropathy market is spread across Asia, North America, Europe, and the Rest of the World. North America has emerged as the leading regional market and is closely followed by Europe. Here is a snapshot of how the market is performing on the regional front.

  • In 2014, the North America market for diabetic nephropathy stood at US$0.9 bn and is expected to reach US$1.3 bn by the end of 2020.
  • Asia, however, is likely to report the fastest growth in the worldwide diabetic nephropathy market in the coming years.
  • China and Japan are the dominating domestic markets for diabetic nephropathy in Asia. The high prevalence of various kidney diseases in these countries is projected to fuel the demand for the diabetic nephropathy therapeutics across Asia in the near future.

Reata Pharmaceuticals Inc., Sanofi, Mitsubishi Tanabe Pharma Corp., Pfizer Inc., Merck & Co. Inc., Abbott Laboratories, AbbVie Inc., Bayer AG, Novartis AG, and Eli Lilly and Co. are some of the key developers of the therapeutics for diabetic nephropathy in the global arena.

Back To Top